Cargando…

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

BACKGROUND: The guidelines on antithrombotic treatment in patients with symptomatic peripheral artery disease (PAD) undergoing peripheral revascularization of the lower extremities were developed based on heterogeneous trials, assessing various dose regimens and recruiting patients who were subjecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauersachs, Rupert, Wu, Olivia, Hawkins, Neil, Bowrin, Kevin, Wojciechowski, Piotr, Clay, Emilie, Huelsebeck, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407972/ https://www.ncbi.nlm.nih.gov/pubmed/34497668 http://dx.doi.org/10.1155/2021/8561350

Ejemplares similares

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England
por: Portas, Laura, et al.
Publicado: (2022)

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
por: Bauersachs, Rupert, et al.
Publicado: (2019)

Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

Rivaroxaban and the EINSTEIN clinical trial programme
por: Cohen, Alexander T., et al.
Publicado: (2019)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
por: Hess, Connie N., et al.
Publicado: (2022)

The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization
por: Serra, Raffaele, et al.
Publicado: (2021)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Peripheral nerve regeneration and intraneural revascularization
por: Caillaud, Martial, et al.
Publicado: (2019)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease
por: Biswas, Minakshi P., et al.
Publicado: (2021)

The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
por: Kadoglou, Nikolaos P. E., et al.
Publicado: (2021)

Revascularization of Peripheral Arteries in Patients with Intermittent Claudication Decreases Inflammatory Biomarkers
por: Poredoš, Pavel, et al.
Publicado: (2023)

Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany — A retrospective cohort study()
por: Bonnemeier, Hendrik, et al.
Publicado: (2019)

Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up
por: Wojtasik-Bakalarz, Joanna, et al.
Publicado: (2019)

Transpedal and Tibiopedal Retrograde Revascularization for Peripheral Vascular Disease
por: Ali, Nawaf M O S, et al.
Publicado: (2022)

Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
por: Savonitto, Stefano, et al.
Publicado: (2020)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Surgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rate
por: Jafarian, Ali, et al.
Publicado: (2015)

The Use of the Fasciocutaneous Flap Harvested From Revascularized Limbs With Peripheral Arterial Disease
por: Hwan Lee, Dong, et al.
Publicado: (2019)

Outcome of Ligation without Revascularization in Pseudoaneurysms of Peripheral Arteries in Intravenous Drug Users
por: Jaiswal, Lokesh Shekher, et al.
Publicado: (2019)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Long‐Term Effectiveness and Safety of Initiating Statin Therapy After Index Revascularization In Patients With Peripheral Arterial Occlusive Disease
por: Peters, Frederik, et al.
Publicado: (2020)

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019)

Association of Ankle-Brachial Indices With Limb Revascularization or Amputation in Patients With Peripheral Artery Disease
por: Moussa Pacha, Homam, et al.
Publicado: (2018)

Endovascular Revascularization Improves the Central Hemodynamics and Augmentation Index in Patients with Peripheral Artery Disease
por: Watanabe, Ken, et al.
Publicado: (2019)

Evaluation of Hyperspectral Imaging for Follow-Up Assessment after Revascularization in Peripheral Artery Disease
por: Grambow, Eberhard, et al.
Publicado: (2022)

Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease
por: Schawe, Larissa, et al.
Publicado: (2022)

Predicting Arterial Thrombotic Events Following Peripheral Revascularization Using Objective Viscoelastic Data
por: Majumdar, Monica, et al.
Publicado: (2022)

Distribution of Peripheral Arterial Disease in Patients Undergoing Endovascular Revascularization for Chronic Limb Threatening Ischaemia: Insights from the Vascular Quality Initiative in Singapore
por: Soon, Shereen X. Y., et al.
Publicado: (2021)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease
por: Kim, Gwang Sil, et al.
Publicado: (2022)

The effect of revascularization on recovery of mitochondrial respiration in peripheral artery disease: a case control study
por: Gratl, Alexandra, et al.
Publicado: (2021)

Comparison of the oxidative profiles before and after revascularization in peripheral arterial disease: a pilot study
por: Takeuchi, Kozo, et al.
Publicado: (2023)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lm2t8e7vnmje19ab39akhhl2rv